Statins in ophthalmology.
Journal article

Statins in ophthalmology.

  • Ooi KG Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia. Electronic address: kenneth.ooi@sydney.edu.au.
  • Khoo P Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia.
  • Vaclavik V Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
  • Watson SL Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia.
  • 2019-02-01
Published in:
  • Survey of ophthalmology. - 2019
English Statins, 3-hydroxy-3-methyl-gutaryl coenzyme A reductase inhibitors, are a class of lipid-lowering drugs with anti-inflammatory, immunomodulatory, and vascular effects. Statins are increasingly being used in the treatment of a variety of medical conditions. We examine the actions of statins on the eye and its associated ophthalmic disorders. Statins can be synthetic or nonsynthetic, and their differentiating derivations may contribute to their varying cholesterol-lowering and pleiotropic effects. There is conflicting evidence on the ocular therapeutic and adverse effects of the statins. Statins may play a role in reducing the burden of dry eye, corneal ulcer scarring, thyroid-associated orbitopathy, glaucoma, uveitis and other associated ocular inflammatory states, cataract, proliferative vitreoretinopathy, diabetic retinopathy, macular degeneration, and choroidal melanoma. Topical preparations of statins can be formulated, thereby extending the range of ocular diseases that may be amenable to treatment. Statins have a relatively safe side effect profile, but rare and serious adverse reactions have been reported with their usage in ophthalmology, including myopathies and rhabdomyolysis with acute renal failure.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/126435
Statistics

Document views: 39 File downloads: